PMID- 34384698
OWN - NLM
STAT- MEDLINE
DCOM- 20220201
LR  - 20220201
IS  - 1477-2566 (Electronic)
IS  - 1465-3249 (Linking)
VI  - 24
IP  - 1
DP  - 2022 Jan
TI  - Safety of allogeneic umbilical cord blood infusions for the treatment of 
      neurological conditions: a systematic review of clinical studies.
PG  - 2-9
LID - S1465-3249(21)00715-5 [pii]
LID - 10.1016/j.jcyt.2021.07.001 [doi]
AB  - BACKGROUND AIMS: Umbilical cord blood (UCB) infusion is being investigated as a 
      treatment for a range of neurological conditions, primarily because of its potent 
      immunomodulatory effects mediated via paracrine signaling. Although initial 
      research mainly utilized autologous UCB, allogeneic samples from a sibling or 
      unrelated donor have now become more common. With the use of allogeneic UCB, 
      questions have arisen surrounding the necessity for human leukocyte antigen (HLA) 
      matching, preparative regimens and immunosuppressant drugs. To investigate the 
      safety of allogeneic UCB for the treatment of neurological conditions and the 
      impact of HLA mismatching and immunosuppresion, the authors conducted a 
      systematic review of the safety of allogeneic UCB infusion for neurological 
      conditions. METHODS: A systematic review of published and gray literature was 
      conducted to investigate the safety of allogeneic UCB infusions for neurological 
      conditions. RESULTS: Authors identified 10 studies using allogeneic UCB to treat 
      autism spectrum disorder, cerebral palsy, stroke, traumatic brain injury and 
      various other conditions. A total of 361 participants (with at least 442 UCB 
      infusions) received a range of HLA-matched/untyped allogeneic units and cell 
      doses, with the majority not administered post-infusion immunosuppression. There 
      were no reported serious adverse events definitely or probably related to the 
      allogeneic UCB infusion, nor later potential complications such as 
      graft-versus-host disease or teratoma formation. CONCLUSIONS: Although 
      variability between studies is high, the available data do not identify safety 
      concerns with allogeneic UCB infusion for the treatment of neurological 
      conditions, even with variable HLA matching or no immunosuppression.
CI  - Copyright (c) 2021 International Society for Cell & Gene Therapy. Published by 
      Elsevier Inc. All rights reserved.
FAU - Paton, Madison C B
AU  - Paton MCB
AD  - Cerebral Palsy Alliance Research Institute, Specialty of Child and Adolescent 
      Health, Sydney Medical School, Faculty of Medicine and Health, University of 
      Sydney, Sydney, Australia. Electronic address: 
      madison.paton@cerebralpalsy.org.au.
FAU - Wall, Donna A
AU  - Wall DA
AD  - Bone Marrow Transplant/Cellular Therapy, Division of Hematology/Oncology, 
      Department of Pediatrics, The Hospital for Sick Children/University of Toronto, 
      Toronto, Canada; Department of Pediatrics, University of Toronto, Toronto, 
      Canada.
FAU - Elwood, Ngaire
AU  - Elwood N
AD  - BMDI Cord Blood Bank, Melbourne, Australia; Murdoch Children's Research 
      Institute, Melbourne, Australia; Department of Pediatrics, University of 
      Melbourne, Melbourne, Australia.
FAU - Chiang, Kuang-Yueh
AU  - Chiang KY
AD  - Bone Marrow Transplant/Cellular Therapy, Division of Hematology/Oncology, 
      Department of Pediatrics, The Hospital for Sick Children/University of Toronto, 
      Toronto, Canada; Department of Pediatrics, University of Toronto, Toronto, 
      Canada.
FAU - Cowie, Genevieve
AU  - Cowie G
AD  - Cerebral Palsy Alliance, Sydney, Australia.
FAU - Novak, Iona
AU  - Novak I
AD  - Cerebral Palsy Alliance Research Institute, Specialty of Child and Adolescent 
      Health, Sydney Medical School, Faculty of Medicine and Health, University of 
      Sydney, Sydney, Australia.
FAU - Finch-Edmondson, Megan
AU  - Finch-Edmondson M
AD  - Cerebral Palsy Alliance Research Institute, Specialty of Child and Adolescent 
      Health, Sydney Medical School, Faculty of Medicine and Health, University of 
      Sydney, Sydney, Australia.
LA  - eng
PT  - Journal Article
PT  - Review
PT  - Systematic Review
DEP - 20210810
PL  - England
TA  - Cytotherapy
JT  - Cytotherapy
JID - 100895309
RN  - 0 (Pharmaceutical Preparations)
SB  - IM
MH  - *Autism Spectrum Disorder
MH  - *Cord Blood Stem Cell Transplantation/adverse effects
MH  - Fetal Blood
MH  - *Graft vs Host Disease/therapy
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - *Pharmaceutical Preparations
OTO - NOTNLM
OT  - allogeneic
OT  - clinical trials
OT  - neurological conditions
OT  - stem cells
OT  - systematic review
OT  - umbilical cord blood
COIS- Declaration of Competing Interest The authors have no commercial, proprietary or 
      financial interest in the products or companies described in this article.
EDAT- 2021/08/14 06:00
MHDA- 2022/02/02 06:00
CRDT- 2021/08/13 05:51
PHST- 2021/05/12 00:00 [received]
PHST- 2021/06/30 00:00 [revised]
PHST- 2021/07/02 00:00 [accepted]
PHST- 2021/08/14 06:00 [pubmed]
PHST- 2022/02/02 06:00 [medline]
PHST- 2021/08/13 05:51 [entrez]
AID - S1465-3249(21)00715-5 [pii]
AID - 10.1016/j.jcyt.2021.07.001 [doi]
PST - ppublish
SO  - Cytotherapy. 2022 Jan;24(1):2-9. doi: 10.1016/j.jcyt.2021.07.001. Epub 2021 Aug 
      10.